By staff writers

June 29, 2011 -- Aspect Imaging has signed an agreement with Cage Chemicals to develop and manufacture Aspect's PhenoQuant line of contrast agents for preclinical research.

The Molecular Imaging Center at the University of Turin in Italy will also develop scientific preclinical applications and protocols to support the use of the agents for molecular imaging using Aspect's M2 compact high-performance MRI system.

M2 has no magnetic fringe field and costs less than traditional MRI systems.

Copyright © 2011

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking